N,N-bis-(3,4-dimethoxybenzyl)amine | 5634-21-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-bis-(3,4-dimethoxybenzyl)amine
• 英文别名: N,N-bis(3,4-dimethoxybenzyl)amine；bis(3,4-dimethoxybenzyl)amine；diveratryl-amine；Diveratryl-amin；1-(3,4-dimethoxyphenyl)-N-[(3,4-dimethoxyphenyl)methyl]methanamine
• CAS: 5634-21-9
• 化学式: C₁₈H₂₃NO₄
• 分子量: 317.385
• InChiKey: ZAHBSOCTGNBCSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N,N-bis-(3,4-dimethoxybenzyl)amine 在 四丁基氟化铵 、 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 12.08h， 生成 2,6-di-(3'-hydroxypropoxy)-4,8-bis(di-N,N-(3',4'-dimethoxybenzyl)amino)pyrimido[5,4-d]pyrimidine
  参考文献：
  名称：

  Resistance-Modifying Agents. 11. Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure−Activity Relationships for Nucleoside Transport Inhibition and Binding to α₁-Acid Glycoprotein

  摘要：

  The cardiovascular and antithrombotic agent dipyridamole (DP) has potential therapeutic utility as a modulator of the activity of antimetabolite antitumor agents by virtue of its inhibition of nucleoside transport. However, the activity of DP can be compromised by binding to the acute phase serum protein, alpha(1)-acid glycoprotein (AGP). Analogues of DP were synthesized and evaluated as inhibitors of H-3-thymidine uptake into L1210 leukamia cells in the presence and absence of 5 mg/mL AGP. Compounds with potency similar to that of DP were identified where the piperidino substituents at the 4,8-positions were replaced by 4'-methoxybenzylamino, 3',4'dimethoxybenzylamino, or piperonylamino groups. Replacement of the diethanolamino groups at the 2,6-positions of DP by alkylamino or alkoxy substituents was tolerated, although at least one oxygen-bearing function (hydroxyl or alkoxy) was required in the side chain for activity comparable to that of DP. Whereas AGP completely ablated the activity of DP, the majority of the newer compounds synthesized retained significant activity in the presence of excess AGP, although replacement of the piperidino groups at the 4,8-positions by N-methylbenzylamino substituents did, in some cases, restore susceptibility to AGP. Selected compounds have been demonstrated to prevent rescue from antifolate cytotoxicity, mediated by nucleoside salvage.

  DOI：

  10.1021/jm040772w
• 作为产物：
  描述：

  3,4-二甲氧基苄胺 在 sodium tetrahydroborate 、 magnesium sulfate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 N,N-bis-(3,4-dimethoxybenzyl)amine
  参考文献：
  名称：

  带有2,4-二甲氧基苄基的邻氨基磺酸氨基磺酸酯的 有效N保护作用†

  摘要：

  氨基磺酸盐在当前药物化学和药物开发的某些领域中是重要的官能团。醇和酚通常通过与以下物质反应而转化为相应的伯氨基磺酸盐（分别为ROSO 2 NH 2和ArOSO 2 NH 2）。氨磺酰氯（H 2 NSO 2 Cl）。O-氨基磺酸酯基团的不稳定性，特别是在碱性条件下，通常将这种方法限制在合成的后期。为使酚O-氨基磺酸盐的合成具有更灵活的方法，已开发了氨基磺酸盐的保护基策略。两个氨基磺酸盐NH质子均被4-甲氧基苄基或2,4-二甲氧基苄基取代。这些N-保护的氨基磺酸盐对氧化剂和还原剂以及碱和亲核试剂是稳定的，因此使得这种掩蔽的氨基磺酸盐适合于多步合成。通过微波加热1,1'-磺酰基双（2-甲基-1 H）合成受保护的氨基磺酸酯（-咪唑）与取代的苯酚反应，得到2-甲基-1 H-咪唑-1-磺酸芳基酯。该咪唑磺酸盐通过与N-甲基化而被N-甲基化。四氟硼酸三甲基氧鎓，这使得随后的 1,2-二甲基咪唑通过二苄基

  DOI：

  10.1039/c2ob26057c

文献信息

• [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE<br/>[FR] COMPOSES, COMPOSITIONS ET PROCEDES DE TRAITEMENT DE MALADIES AMYLOIDES ET DE SYNUCLEINOPATHIES, NOTAMMENT DE LA MALADIE D'ALZHEIMER, DU DIABETE DE TYPE 2 ET DE LA MALADIE DE PARKINSON
  申请人：PROTEOTECH INC

  公开号：WO2003101927A1

  公开（公告）日：2003-12-11

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aß amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinophathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双-和三-二羟基芳基化合物及其亚甲二氧基类似物和药用可接受酯，它们的合成，含有它们的药物组合物，以及它们在治疗淀粉样疾病，特别是Aß淀粉样病变，如阿尔茨海默病中观察到的，IAPP淀粉样病变，如2型糖尿病中观察到的，以及α-突触核病，如帕金森病中观察到的，以及用于制造用于此类治疗的药物。
• Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)
  作者：Ganesha Rai、Kyle R. Brimacombe、Bryan T. Mott、Daniel J. Urban、Xin Hu、Shyh-Ming Yang、Tobie D. Lee、Dorian M. Cheff、Jennifer Kouznetsova、Gloria A. Benavides、Katie Pohida、Eric J. Kuenstner、Diane K. Luci、Christine M. Lukacs、Douglas R. Davies、David M. Dranow、Hu Zhu、Gary Sulikowski、William J. Moore、Gordon M. Stott、Andrew J. Flint、Matthew D. Hall、Victor M. Darley-Usmar、Leonard M. Neckers、Chi V. Dang、Alex G. Waterson、Anton Simeonov、Ajit Jadhav、David J. Maloney

  DOI：10.1021/acs.jmedchem.7b00941

  日期：2017.11.22

  pyrazole-based inhibitors of human lactate dehydrogenase (LDH). Utilization of a quantitative high-throughput screening paradigm facilitated hit identification, while structure-based design and multiparameter optimization enabled the development of compounds with potent enzymatic and cell-based inhibition of LDH enzymatic activity. Lead compounds such as 63 exhibit low nM inhibition of both LDHA and

  我们报告了一系列新型吡唑类人乳酸脱氢酶 (LDH) 抑制剂的发现和药物化学优化。定量高通量筛选范例的利用促进了命中鉴定，而基于结构的设计和多参数优化使得能够开发出对 LDH 酶活性具有有效酶促和基于细胞抑制作用的化合物。 63等先导化合物在 MiaPaCa2 胰腺癌和 A673 肉瘤细胞中表现出对 LDHA 和 LDHB 的低 nM 抑制作用、对乳酸产生的亚微摩尔抑制作用以及对糖酵解的抑制作用。此外，使用细胞热位移测定 (CETSA) 证明了先导化合物对 LDHA 的强大靶向作用，并通过 SPR 确定了药物-靶标停留时间。对这些数据的分析表明，药物靶点停留时间（解离速率）可能是获得对该癌症代谢靶点的有效细胞抑制的一个重要因素。
• RAPID REDUCTION OF NITRILES TO PRIMARY AMINES WITH NICKEL BORIDE AT AMBIENT TEMPERATURE[1]
  作者：Jitender M. Khurana、Gagan Kukreja

  DOI：10.1081/scc-120003619

  日期：2002.1

  ABSTRACT Reduction of a variety of nitriles to their corresponding primary amines can be achieved with nickel boride generated in situ in dry ethanol at ambient temperature. The reductions are very rapid and chemoselective.

  摘要 在室温下，在无水乙醇中原位生成硼化镍，可以将各种腈还原为相应的伯胺。减少非常迅速且具有化学选择性。
• Stereoselective conjugate addition reactions of lithium amides to α,β-unsaturated chiral iron acyl complexes [(η5-C5H5)Fe(CO)(PPh3)(COCHCHR)]
  作者：Stephen G. Davies、Jairton Dupont、Robert J.C. Easton、Osamu Ichihara、Jeffrey M. McKenna、Andrew D. Smith、José A.A. de Sousa

  DOI：10.1016/j.jorganchem.2004.04.046

  日期：2004.11

  Conjugate addition of achiral lithium dimethylamide to the chiral iron cinnamoyl complexes (S,E)- and (S,Z)-[(η5-C5H5)Fe(CO)(PPh3)(COCHCHPh)] proceeds with high diastereoselectivity, with this protocol being used to establish unambiguously the absolute configuration of Winterstein’s acid (3-N,N-dimethylamino-3-phenylpropanoic acid) as (R). The highly diastereoselective conjugate addition of lithium

  共轭加成的非手性二甲基氨基锂的手性铁络合物肉桂（小号，ë） -和（小号，Ž） - [（η 5 -C 5 H ^ 5）的Fe（CO）（PPH 3）（COCHCHPh）]进行以高非对映选择性，使用该方案可以明确地确定温特斯坦酸（3- N，N-二甲基氨基-3-苯基丙酸）的绝对构型为（R）。锂N-苄基-N的高度非对映选择性共轭加成-三甲基甲硅烷基酰胺形成一系列α，β-不饱和铁酰基络合物，然后通过烷基化或醛醇缩合反应原位合成衍生的烯酸酯，这也促进了顺式和反式-β-内酰胺的立体选择性合成。该方法已被用于实现（±）-橄榄酸和（±）-硫霉素的形式不对称合成。手性氨基化锂的添加来自伯和仲胺衍生的铁巴豆络合物[（η 5 -C 5 H ^ 5）的Fe（CO）（PPH 3）（COCHCHMe）]表示锂Ñ -α-甲基苄显示低水平的对映体识别，而锂N-3,4-二甲氧基苄Ñ -α-甲基苄基酰胺和锂Ñ苄基Ñ -α-甲基苄
• Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and parkinson's disease
  申请人：——

  公开号：US20040127555A1

  公开（公告）日：2004-07-01

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&bgr; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双和三羟基芳基化合物及其亚甲二氧基类似物和药学上可接受的酯，其合成方法，包含它们的药物组成物，以及它们在治疗淀粉样疾病中的应用，特别是Aβ淀粉样蛋白病，如阿尔茨海默病，IAPP淀粉样蛋白病，如2型糖尿病中观察到的，以及突触核蛋白病，如帕金森病中观察到的，以及用于制造此类治疗药物。